guanfacine has been researched along with Childhood Tic Disorders in 11 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Guanfacine appears to be a safe and effective treatment for children with tic disorders and ADHD." | 2.70 | A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. ( Arnsten, AF; Chappell, PB; Cohen, DJ; Katsovich, L; Kim, YS; Leckman, JF; Scahill, L; Schultz, RT; Shepherd, E, 2001) |
| " In one study, tics limited further dosage increases of methylphenidate." | 2.58 | Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. ( Osland, ST; Pringsheim, T; Steeves, TD, 2018) |
| " While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs." | 2.49 | Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. ( Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013) |
| "Risperidone and clonidine were the most commonly recommended medications for tic disorders over the study period, with 36,868 and 35,500 recommendations in 2016, respectively." | 1.51 | Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. ( Cothros, N; Martino, D; McMorris, C; Pringsheim, T; Stewart, D; Tehrani, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Roessner, V | 1 |
| Eichele, H | 1 |
| Stern, JS | 1 |
| Skov, L | 1 |
| Rizzo, R | 1 |
| Debes, NM | 1 |
| Nagy, P | 1 |
| Cavanna, AE | 1 |
| Termine, C | 1 |
| Ganos, C | 1 |
| Münchau, A | 1 |
| Szejko, N | 1 |
| Cath, D | 1 |
| Müller-Vahl, KR | 1 |
| Verdellen, C | 1 |
| Hartmann, A | 1 |
| Rothenberger, A | 1 |
| Hoekstra, PJ | 1 |
| Plessen, KJ | 1 |
| Cothros, N | 1 |
| Martino, D | 1 |
| McMorris, C | 1 |
| Stewart, D | 1 |
| Tehrani, A | 1 |
| Pringsheim, T | 3 |
| de Groof, C | 1 |
| De La Marche, W | 1 |
| Danckaerts, M | 2 |
| Yang, C | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Yu, D | 1 |
| Li, J | 1 |
| Zhang, L | 1 |
| Murphy, TK | 1 |
| Fernandez, TV | 1 |
| Coffey, BJ | 1 |
| Rahman, O | 1 |
| Gavaletz, A | 1 |
| Hanks, CE | 1 |
| Tillberg, CS | 1 |
| Gomez, LI | 1 |
| Sukhodolsky, DG | 1 |
| Katsovich, L | 2 |
| Scahill, L | 3 |
| Osland, ST | 1 |
| Steeves, TD | 1 |
| Doja, A | 1 |
| Gorman, D | 1 |
| McKinlay, D | 1 |
| Day, L | 1 |
| Billinghurst, L | 1 |
| Carroll, A | 1 |
| Dion, Y | 1 |
| Luscombe, S | 1 |
| Steeves, T | 1 |
| Sandor, P | 1 |
| Cortese, S | 1 |
| Holtmann, M | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Dittmann, RW | 1 |
| Graham, J | 1 |
| Taylor, E | 1 |
| Sergeant, J | 1 |
| Boon-yasidhi, V | 1 |
| Kim, YS | 2 |
| Newcorn, JH | 1 |
| Schulz, K | 1 |
| Harrison, M | 1 |
| DeBellis, MD | 1 |
| Udarbe, JK | 1 |
| Halperin, JM | 1 |
| Chappell, PB | 1 |
| Schultz, RT | 1 |
| Shepherd, E | 1 |
| Arnsten, AF | 1 |
| Cohen, DJ | 1 |
| Leckman, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Finalizing and Testing an Online Therapist Training and Assistance Program to Facilitate Implementation of Comprehensive Behavioral Intervention for Tic Disorders[NCT05547854] | 234 participants (Anticipated) | Interventional | 2023-06-27 | Recruiting | |||
| Therapeutic Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Pediatric Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Cohorts (ADHD): a Randomized, Sham-controlled Study.[NCT06069323] | 80 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
7 reviews available for guanfacine and Childhood Tic Disorders
| Article | Year |
|---|---|
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Male; Rispe | 2022 |
[Effectiveness of guanfacin on comorbid disorders in children and adolescents with adhd: a systematic literature review].
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anxiety Disorders; Attention Deficit Disorder with | 2019 |
Interventions for tic disorders: An updated overview of systematic reviews and meta analyses.
Topics: Antipsychotic Agents; Aripiprazole; Child; Cost-Benefit Analysis; Exercise; Guanfacine; Humans; Meta | 2020 |
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2018 |
Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Antipsychotic Agents; Canada; Child; Clonidine; Evidenc | 2012 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2013 |
Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Anxiety Disorders; Attention Defici | 1998 |
2 trials available for guanfacine and Childhood Tic Disorders
| Article | Year |
|---|---|
Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Child; Double-Blind Method; Female; Guanfacine; Hu | 2017 |
A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Child; Comorbi | 2001 |
2 other studies available for guanfacine and Childhood Tic Disorders
| Article | Year |
|---|---|
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Guanfacine; Humans; | 2019 |
An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
Topics: Adolescent; Adrenergic alpha-Agonists; Attention Deficit Disorder with Hyperactivity; Blood Pressure | 2005 |